AtaiBeckley Inc. Common Stock (ATAI) is a publicly traded Healthcare sector company. As of May 21, 2026, ATAI trades at $4.14 with a market cap of $1.53B and a P/E ratio of -4.84. ATAI moved +3.41% today. Year to date, ATAI is +5.68%; over the trailing twelve months it is +99.51%. Its 52-week range spans $1.03 to $6.75. Analyst consensus is strong buy with an average price target of $14.90. Rallies surfaces ATAI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Jefferies Highlights H2 2026 Pivotal Readouts in AtaiBeckley Pipeline: Jefferies indicated that AtaiBeckley’s clinical pipeline has advanced toward several late-stage data catalysts, with pivotal trial readouts slated for the second half of 2026. The broker highlighted progression across multiple psychedelic therapy candidates, potentially unlocking near-term valuation inflection points for the venture.
| Metric | Value |
|---|---|
| Price | $4.14 |
| Market Cap | $1.53B |
| P/E Ratio | -4.84 |
| EPS | $-0.83 |
| Dividend Yield | 0.00% |
| 52-Week High | $6.75 |
| 52-Week Low | $1.03 |
| Volume | 4.53K |
| Avg Volume | 0 |
| Revenue (TTM) | $3.02M |
| Net Income | $-154.30M |
| Gross Margin | 0.00% |
11 analysts cover ATAI: 0 strong buy, 11 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $14.90.